Report Overview

The Liver diseases drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Hepatic complications due to alcoholism is common in Kenya. There is an unexpected number of cases of chronic aggressive hepatitis and cirrhosis. The prevalence of HBV (Hepatitis B Virus) infection in Kenya is estimated to be between 1% to 5%, although rates among specific high-risk populations (HIV co-infected, drug abusers, jaundiced patients seeking medical care) are much higher. Changing lifestyle such as increasing consumption of alcohol, unhealthy diets have increased the incidences of liver disease. The prevalence of heavy drinking is approximately 12.6% in Kenya. Men are more likely to engage in heavy episodic drinking than women .The highest proportion is reported in the 1829-year age group.



Market Drivers

Liver Diseases drug market is driven by the high prevalence of liver diseases like Hepatitis and Liver Cirrhosis due to alcoholism in Kenya. According to the latest WHO data published in 2018 Liver Disease Deaths in Kenya reached 2,514 or 0.98% of total deaths. The age adjusted Death Rate is 11.47 per 100,000 of population.

Increase in Government initiatives like screening for hepatitis among high-risk populations and providing clinical care for patients who have tested positive is expected to fuel growth in the hepatitis drug market.

With the increasing prevalence of liver diseases, government and other not-for-profit organizations are playing a crucial role in the rising awareness about liver diseases. Hence all these organizations are found promoting the awareness of the liver-related diseases and support for research and development for the prevention, treatment and cure of liver diseases.

Growing alcohol consumption has increased incidences of liver diseases which would propel the growth of liver disease treatment market in future.

However, the side effects caused by several drug are restraining market growth. The outbreak of COVID-19 has decreased diagnosis, screening and follow-up of patients suffering from hepatitis which has negative outcomes of health in patients with hepatitis.